{"entity":{"id":"simcere","kind":"company","name":"Simcere Pharmaceutical","aka":["Jiangsu Simcere Pharmaceutical Co., Ltd.","Simcere Zaiming"],"tldr":"Simcere is a Nanjing-based pharmaceutical company whose oncology arm, Simcere Zaiming, is running the phase 3 SIMRISE trial of the oral SERD SIM0270 with everolimus in ER-positive breast cancer and markets the anti-PD-1 antibody enlonstobart in China.","summary":"Simcere Pharmaceutical Group, based in Nanjing and listed in Hong Kong, sells medicines across oncology, neurology and autoimmune disease in China and runs its cancer research through the subsidiary Simcere Zaiming. Its oncology portfolio includes enlonstobart, an anti-PD-1 antibody approved in China for previously treated cervical cancer, the Chinese rights to the myeloprotective drug trilaciclib, and SIM0270, an oral selective oestrogen receptor degrader in the phase 3 SIMRISE trial with everolimus for ER-positive, HER2-negative advanced breast cancer. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.simcere.com/en/"},{"label":"ClinicalTrials.gov: trials led by Jiangsu Simcere Pharmaceutical","url":"https://clinicaltrials.gov/search?lead=Simcere"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["breast-hr-positive","cervical"],"sections":["targeted-therapy","immunotherapy"],"technologies":[],"targets":[],"drugs":["sim0270","recombinant-human-endostatin"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["simrise","nct07361003","nct04914598"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Nanjing","country":"CN","companyType":"pharma","website":"https://www.simcere.com/en/","stage":"public","investors":[],"funding":[]},"route":"/companies/simcere/","neighbours":{"cancer":[{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"}],"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"},{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"drug":[{"id":"recombinant-human-endostatin","kind":"drug","name":"Recombinant human endostatin","route":"/drugs/recombinant-human-endostatin/"},{"id":"sim0270","kind":"drug","name":"SIM0270","route":"/drugs/sim0270/"}],"trial":[{"id":"nct07361003","kind":"trial","name":"A Phase Ib/III Study of Suvemcitug Plus FTD/TPI in Participants With Refractory Metastatic Colorectal Cancer","route":"/trials/nct07361003/"},{"id":"nct04914598","kind":"trial","name":"A Phase Ⅲ Clinical Study of Combined Cisplatin Versus Placebo Combined With Intracavitary Cisplatin Injection in the Treatment of Malignant Pleural Effusions","route":"/trials/nct04914598/"},{"id":"simrise","kind":"trial","name":"A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)","route":"/trials/simrise/"},{"id":"nct06698965","kind":"trial","name":"Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Trilaciclib, Envafolimab, Etoposide, and C","route":"/trials/nct06698965/"},{"id":"nct06370416","kind":"trial","name":"the Prevention of Bone Marrow Suppression Caused by Chemotherapy in Advanced NSCLC With Trilaciclib","route":"/trials/nct06370416/"}]}}